Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ADVENTRX Engages Canaccord Genuity as Product Acquisition Advisor
.
Companies:Adventrx Pharmaceuticals, Inc.CANACCORD FINANCIAL INC..Related Quotes
Symbol Price Change
ANX 2.03 0.00
Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Tuesday August 10, 2010, 8:00 am
SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has engaged the investment banking firm Canaccord Genuity Inc. to advise the Company and its Board of Directors as it seeks to expand its product candidate pipeline. To assist in evaluating potential acquisition and merger opportunities, the ADVENTRX Board of Directors has formed a Special Committee, which includes Eric K. Rowinsky and Michael M. Goldberg and is chaired by Odysseas D. Kostas.
"The financial results we recently reported, including over $30 million in cash at June 30, provide us substantial leverage in what remains a difficult financing environment. We believe many programs with substantial potential are available at attractive valuations and that now is the right time to explore expanding our pipeline of assets," said Brian M. Culley, Chief Executive Officer of ADVENTRX.
"We are excited to serve ADVENTRX as it seeks to expand its pipeline," said David Schechner, Managing Director at Canaccord Genuity. "In the current market, there are many valuable product candidates and technologies that are not being fully developed, and we believe this provides ADVENTRX an excellent opportunity to grow its business."
Parties wishing to discuss a potential transaction should contact David Schechner, at 617-788-1584.
ADVENTRX Pharmaceuticals to Present at the 2010 Southern California Investor Conference on August 17
SAN DIEGO, Aug. 9 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) will present to investors as part of the 2010 Southern California Investor Conference on August 17, 2010 at 9:30 a.m. Pacific time in Cabana Room No. 4 at the Island Hotel in Newport Beach, California.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.
Next news from ANX will be good news..
company is ready to bring good news, after split, and financials.. next quarter good news ahead.. imo
I bought more on these financial facts.. (strong balance)
Anx looks to merge, and is an take-over candidate itselve.. imo
Oke, thx..
the assistens here are they still on board ?
(becourse they didnt post for a long time..)
Hope they are and help to make this ANX board a winning one..
looks good.. 2.20 HOD.. nice vollume
I-box a little updated, whit new O/S and RT chart..
I-box in construction.. lol
Grtz.. leon
I agree... big rally soon..
after RS company dilute to +15 milion shares, company now is healty and trayding under cash position..(@+40 mil).. imo this is a $6 stock.. sooner or later it will..
a little down today, for the not-believers.. up big soon, is gona happen imo..
gltya..
I keep on buying..
if TPHM dilute shares in that period they are gilty..So is Harold
I believe they dilute from the first moment after the news came out, and that should be investigated... It could be posible if Harold is used and payed for this fraud..
SEC invesigation for this company.. and CEO..
28K traded under 2 dollar, all other vollume above.. goooooo
2.10 looks like a rally starts..
2.04 RT, break is posible today..
We have been a few times on this point, hope it finaly (now) breaks hard..
This is in my opinion a $6 stock..
youre right.. I am in @ 1.30
Good luck, This could be a nice start..
start Rally.. go 2 dollar..
Strange is it not.. 5 months nothing.. We all paid for all he is spending now..
news before or on 5 aug..
Avii has news.. I can feel it.. (lol)
Aug 5, 2010
BMO Capital Markets Focus on Healthcare Conference
Barron's wrote: "AVI is looking for a large partner to further the
development of its muscular-dystrophy drug, and the government contract could
help that effort. One potential partner is Pfizer (PFE), which is eager to
bolster its unimpressive drug pipeline and has an initiative targeting rare
diseases."
This seems likely, especially in light of the fact that one of PFE's target diseases under their rare disease initiative is DMD.
Barron's did get one fact not quite right though - they described AVI's cash burn rate as $25M/year. This ($25M/yr) has actually been their operating budget for the last several years - their net cash burn rate has been about half this - $12 - $14M/yr - due to a fairly steady govt contract revenue, and they currently have over $40M in cash.
With the two NEW larger govt contracts ($18M for flu and $291M for ebola / marburg), they should be able to reduce their net burn rate substantially, if not eliminate it entirely. I believe most if not all of the $18M flu contract is intended to be spent entirely this year (since the larger follow-on award is anticipated by Dec 30, 2010, per govt RFP), and of the $291M Ebola / Marburg contract, the first $80M is released to be spent over the next 18 months. BOE, assuming that 20% of this ($80M) can be spent over the next 6 months, and assuming $4M of the flu award has already been spent, we should see a total of about $30M spent over the next 6 months on these two projects. It will be interesting to hear at the upcoming quarterly conf call how this new revenue stream (more than 2x AVI's previous operating budget) will affect earnings guidance.
I copyed this from yahoo-finance from Dr_mysterio.. thx I wanted to share this good posting on I-Hub..
Gltya..
explosion soon..
I seen this order to., and bought in..
ANX Today's Focus Stock on MicroStockProfit.com
press release
July 21, 2010, 6:50 a.m. EDT · Recommend · Post:
ADVENTRX Pharmaceuticals Inc. is Today's Focus Stock on MicroStockProfit.com
DALLAS, Jul 21, 2010 (GlobeNewswire via COMTEX) -- MicroStockProfit.com announces an investment report featuring ADVENTRX Pharmaceuticals Inc. /quotes/comstock/14*!anx/quotes/nls/anx (ANX 1.76, -0.05, -2.76%) . The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.
Our trade alerts and ideas are provided free to investors. Simply use your email address to subscribe with http://www.microstockprofit.com to get the inside track on our next red-hot alert.
The full report is available at: http://www.microstockprofit.com/lp/ANX
ANX is trading above its 13-day moving average. While this is normally considered to be a bullish sign, the moving average is downward sloping, which means that investors have been liquidating shares during this time period and tempers the bullishness of the signal.
ADVENTRX Pharmaceuticals Inc. (ANX) is a development-stage biopharmaceutical company. The Company's business is focused on in-licensing, developing and commercializing product candidates for the treatment of cancer. Its lead product candidates, ANX-530 and ANX-514, are emulsion formulations of marketed chemotherapy drugs. ANX is focused primarily on evaluating strategic options, including the sale or exclusive license of one or more of its product candidate programs, a strategic business merger and other similar transactions. In October 2008, ANX announced that it had discontinued active work on all product candidates other than ANX-530 and ANX-514. Its wholly owned subsidiaries include SD Pharmaceuticals Inc. (SDP) and ANX (Europe) Ltd.
Message Board Search for ANX: http://www.boardcentral.com/boards/ANX
In the report, the analyst notes:
"ANX's net loss applicable to common stock for the first quarter of 2010 was $4.9 million, or $0.48 per share, compared to a net loss applicable to common stock of $3.2 million, or $0.87 per share, for the same period in 2009. Included in the net loss applicable to common stock for the first quarter of 2010 was a non-cash, deemed dividend expense of $2.5 million incurred in connection with the Company's January 2010 equity financing.
"ANX recently announced the results of stability tests performed on samples of ANX-530 (vinorelbine injectable emulsion), or Exelbine(TM), manufactured at the Company's intended commercial manufacturing site. The nine-month stability data are on track to support the submission of a New Drug Application (NDA) for Exelbine."
To read the entire report visit: http://www.microstockprofit.com/lp/ANX
See what investors are saying about ANX at penny stock forum
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: MicroStockProfit.com
CONTACT: MicroStockProfit.com
Brian Johnson
1-888-307-2850
info@microstockprofit.com
Anx has now 30 milion in cash... Anx can move quicker FDA 1-2-3 less risk it can fail..
15.5 Milion O/S
No Debt..
the D should be off soon..
LHA Life Sciences & Med Tech Day 2010
July 20, 2010
http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=160292
Jul 28, 2010 Annual Meeting of Stockholders - 10:00AM EDT
I think for that, or on that date news,.. and posible voting on R/S.. Its posible its not nessesary.. on good PR., or buy back shares or merger..
65%-35%,, place your bets.. lol
I am in monday..
gltya..
investigation also on the board assistents here.. why arnt they posting here anymore ?
If all he did is legal in the states, I move over.. HE SHOULD BE IN JAIL FOR A LONG TIME..
we still on track to break $ 2 hard..
soon green today imo.
This stock was at 15 April.. (2 months ago = 42 trading days) at $6.80 so more than 70% lost.. a lift up in the 3/4 range would be more realistic for the moment..
Stock Activity Alert for Adventrx Pharmaceuticals (ANX)
Published on 07/13/2010 by Leo Goldman
Shares of ANX touched the 50-day moving average from below but failed to traverse above the widely watched resistance line of $2.00. If the stock stays below the critical 50-day moving average, then investors may continue to sell the shares in anticipation of a downward price move.
Shares of Adventrx Pharmaceuticals closed at $1.78 in the previous trading session and opened today at $1.75. ANX is currently trading at $1.98, up $0.20 (+11.24%) in today's trading session. The shares of the stock are trading between $1.75 and $2.04. Today's price shift was accompanied by a volume of 689,557 shares which is greater than the average volume of 574,644 shares.
(we will move above $2 hard tomorow.. ) becourse there was no resisance at 2 we were already on 2.04
ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX)After Hours: 2.00 +0.02 (+1.00%) 6:31PM EDT
looks like big investors taking a stake..
Get ready for a nice recover jump up..
Its posible.. all looks great.. up..
2 Dollar here we com..